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Abstract
Background: The aim of this study was to analyse willingness to pay (WTP) and ability to pay (ATP) for ACT
for children below five years of age in a rural setting in Tanzania before the introduction of artemisinin-based
combination therapy (ACT) as first-line treatment for uncomplicated malaria. Socio-economic factors associated
with WTP and expectations on anti-malaria drugs, including ACT, were also explored.
Methods: Structured interviews and focus group discussions were held with mothers, household heads, health-
care workers and village leaders in Ishozi, Gera and Ishunju wards in north-west Tanzania in 2004. Contingent
valuation method (CVM) was used with "take-it-or-leave-it" as the eliciting method, expressed as WTP for a full
course of ACT for a child and households' opportunity cost of ACT was used to assess ATP. The study included
descriptive analyses with multivariate adjustment for potential confounding factors.
Results: Among 265 mothers and household heads, 244 (92%, CI = 88%–95%) were willing to pay Tanzanian
Shillings (TSh) 500 (US$ 0.46) for a child's dose of ACT, but only 55% (49%–61%) were willing to pay more than
TSh 500. Mothers were more often willing to pay than male household heads (adjusted odds ratio = 2.1, CI =
1.2–3.6). Socio-economic status had no significant effect on WTP. The median annual non-subsidized ACT cost
for clinical malaria episodes in an average household was calculated as US$ 6.0, which would represent 0.9% of
the average total consumption expenditures as estimated from official data in 2001. The cost of non-subsidized
ACT represented 7.0% of reported total annual expenditure on food and 33.0% of total annual expenditure on
health care.
"Rapid effect," "no adverse effect" and "inexpensive" were the most desired features of an anti-malarial drug.
Conclusion: WTP for ACT in this study was less than its real cost and a subsidy is, therefore, needed to enable
its equitable affordability. The decision taken in Tanzania to subsidize Coartem® fully at governmental health care
facilities and at a consumer price of TSh 300–500 (US$ 0.28–0.46) at special designated shops through the
programme of Accredited Drug Dispensing Outlets (ADDOs) appears to be well founded.
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Background
Malaria constitutes a major burden on individuals and on
the community in low-income countries. In Tanzania, it
has been estimated that 1% of GDP is spent on the dis-
ease. For comparison, total health expenditure in Tanza-
nia constitutes about 4% of GDP. 71% of the total
expenditure on malaria is from private sources [1].
In sub-Saharan Africa, the utilization of ineffective drugs
in recent years has led to treatment failures and elevated
rates of mortality, particularly among young children
[2,3]. Artemisinin-based combination therapy (ACT) is,
therefore, recommended as the first-line anti-malarial
treatment strategy in most parts of sub-Saharan Africa [4].
Efficacy and effectiveness studies have shown that ACT
provides cure rates of over 90% [5-7] and generally, it is
also well tolerated [8,9]. However, good quality of health
care is critical to ensure efficacy and prevent parasitic
resistance to the anti-malarial drugs, by limiting over-
treatment and unnecessary drug exposure, as well as
ensuring compliance to standard treatment doses.
The cost of artemisinin derivatives is a limiting factor for
the affordability and optimal use of ACT. Various forms of
ACT are 5–10-fold more costly compared with the previ-
ously recommended treatments, chloroquine or sul-
phadoxine/pyrimethamine (SP). Coartem® (artemether-
lumefantrine), a co-formulated ACT, was announced in
2006 to be available at a reduced public market price at an
average of US$ 1.0 per adult/child treatment course [10].
Another co-formulated ACT consisting of artesunate and
amodiaquine (ART-AQ) was announced in 2007 to be
available at a market price below US$ 0.5 per child treat-
ment and US$ 1.0 per adult treatment [11]. Access and
affordability are critical for optimal compliance to the
new treatment strategy and an important issue is how
much people are willing and able to pay for ACT. Studies
on willingness to pay (WTP) and ability to pay (ATP) for
ACT are needed to guide financial strategies to ensure
access to recommended malaria treatments for all.
Two studies on WTP for malaria combination therapies
have been published from Africa [12,13]. They assessed
WTP among household heads [12] and mothers [13]
respectively, but did not explore ATP. Both studies con-
cluded that the WTP and the actual market price of ACT
diverge and that subsidies are needed.
The present study estimates and compares WTP for com-
bination therapy among both mothers and household
heads and provides information on ATP from household
heads in an area not previously reached by ACT at the time
of the study (2004). The study also compares annual
household expenditures on ACT by using different cost
scenarios and relates them to WTP and to official data on
total annual rural household consumption expenditure in
Tanzania as well as to reported household expenditures in
the study area. Perceptions of anti-malarial drugs and the
treatment-decision process in the family are also explored.
Methods
Study site
The study was conducted in Ishozi, Gera and Ishunju
wards (small administrative units) in Missenye District in
Kagera Region in April 2004. The district was selected by
convenience. It is a rural district and it is well representa-
tive of the region, which is mainly agricultural. Coffee is a
main cash crop and the staple food is plantain and beans.
Parts of the region are difficult to access due to poor roads
and many rural parts lack electricity. The wards are situ-
ated at an altitude of about 1200 meters above sea level
and have a total population of 15 000. There are 11 vil-
lages in the three wards. The nearest town, Bukoba, is 20–
30 km away. At the time of the data collection in 2004, the
fare of traveling to Bukoba by public transport was Tanza-
nian Shillings (TSh) 500 to 1000 (US$ 0.46–0.92),
depending on the villages' location.
The vast majority of the people in the area are peasants. At
the time of the study the price per kilo of coffee was TSh
200 (US$ 0.18). During the past decade the market price
of coffee had decreased substantially and, therefore, the
availability of cash had declined. The agricultural yield in
general had also gone down. Overall, income had
decreased and expenses increased in the region. Except for
coffee, crops are mainly used for home consumption.
There are eight dispensaries in the area: two government-
run, one private and five run by Patage, a Non-Govern-
mental Organization (NGO). Children get free services at
the government health care facilities. The NGO supports
orphans with free health care and education. All other
services are charged for. There is one private pharmacy in
the area, placed in Ishozi ward. The pharmacy receives
about 50 customers per week. There are also a number of
"unofficial" drug vendors in the region.
Malaria transmission occurs throughout the year but with
peak transmission during and after the rainy seasons,
which commonly occur March to May and October to
December [14].
ACT was largely unknown to the local people at the time
of the study. SP was the first-line malaria treatment and
was well known to the people. Fansidar, the most com-
mon brand of SP, could be bought at a price from TSh 200
(US$ 0.18) per child treatment dose. The only artemisinin
derivate available was Artemedine® (artemether), pro-
duced in China. This monotherapy could be bought in
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Bukoba at TSh 6000 (US$ 5.51) per package containing
12 tablets of 50 mg.
Qualitative data collection
Two focus group discussions (FGD) were conducted in
Nyarugongo village in Ishozi ward. One FGD included
seven men (25–45 years old) whereas the other included
eight women (25–45 years old). The FGDs provided opin-
ions and perceptions on malaria, its treatment and the
need for new anti-malarial drugs, which were used when
designing the questionnaires for the quantitative data col-
lection.
In-depth interviews were held with village leaders from
four out of five villages that were later selected for the
quantitative data collection. One village leader was not
available. The four village leaders were all men and had
been in their position from 4 to 24 years.
In-depth interviews were also conducted with four health-
care workers at four different dispensaries, two govern-
mental and two run by the NGO. Two were nurses, one a
midwife and one a clinical assistant. The pharmacist in the
pharmacy was also interviewed. The drug vendors, who
have continued to sell chloroquine after its official with-
drawal from the market in 2001, were not willing to par-
ticipate in this study, since they were reluctant to answer
questions about their activities.
Quantitative data collection
The data collection took place in April 2004 during the
peak season for malaria transmission. By purposive selec-
tion on the basis of their accessibility and representative-
ness of the target population, the villages Kashaka,
Kashambya, Kashekya, Katano and Ishunju were selected
to represent the three wards. In each village 25–35 moth-
ers of children under five years of age and 25–35 heads of
households with children under five years of age were tar-
geted depending on the size of the village. By starting in
the village center and proceeding randomly from house-
hold to household towards the periphery of the village
and by alternating the type of respondent for each house-
hold, a total number of 135 mothers and 134 heads of dif-
ferent households were included in the study. Only one
respondent, either a mother of a child under five years of
age or the financial head, was randomly selected from
each household.
Two different questionnaires in the national language
Kiswahili were used, one for mothers and one for house-
hold heads. The local language Kihaya was used when it
was needed to clarify the questions to the respondents.
Most questions were close-ended. Questions covered
household characteristics, willingness to pay for malaria
treatment for children as explained below, knowledge on
and perceptions of malaria, decision-making processes in
the household and preferences of characteristics of new
anti-malarial drugs. The term "homa ya malaria" was used
when referring to malaria and the term was defined
according to the local perception of the disease. House-
hold characteristics included household size and compo-
sition, education and occupation of the respondents and
household expenditures.
Contingent valuation method (CVM), a survey-based
method with hypothetical situations to determine indi-
viduals' monetary valuation of health care or health states,
was used to elicit WTP [15-17]. "Take it or leave it"
(TIOLI) was used as eliciting method.
To assess WTP for ACT, a scenario was demonstrated
wherein a child in the household is suffering from malaria
and the interviewee receives information about ACT from
a neighbour who is also a health-care worker. The neigh-
bour describes ACT as a drug combination that treats
malaria efficiently and quickly without serious side
effects. Also its relative high cost was explained. The TIOLI
method was then used whereby the respondent was asked
if he/she would buy ACT for TSh 500. If yes, the price was
raised to TSh 1000 and then to TSh 2000 if accepting the
previous level. Finally, after accepting to pay TSh 2000 or
following a rejection of a bid, the respondent was asked to
mention the maximum amount he/she was willing to pay
for ACT. The levels of 500, 1000 and 2000 were selected
to simplify the data collection and to clearly distinguish
major differences in WTP. The follow-up question was
included to provide an opportunity for the respondents to
state their level of WTP more precisely.
Respondents willing to pay more than TSh 500 were
assumed to afford ACT. In the multivariate analysis the
respondents were classified into two groups to explore if
associated characteristics influenced WTP: a) willing to
pay less or equal to TSh 500 and b) willing to pay more
than TSh 500 for ACT.
The economic level of the households was used as a local
relative indicator of wealth among the included house-
holds. It was assessed by retrieving information from the
heads using questionnaires on monthly expenditures on
food, transport and half-yearly expenditures on health
care, clothes and contributions. These areas of expendi-
ture were selected based on information on the common
local main expenditures items.
Data analysis
The data was entered, prepared and analyzed by bivariate
and multivariate approaches using the statistical compu-
ter programme SPSS. Logistic regression was used to ana-
lyze different variables' association with WTP. The
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dependent variable was WTP ≤ TSh 500 respective WTP >
TSh 500. The independent variables were household sta-
tus, occupation, education, household size and number
of children. The results were expressed as proportions
with 95% confidence intervals. Missing data and "no
answer" and "do not know" were excluded.
In the analysis, each household was allocated to an eco-
nomic quintile according to the average household
expenditure per household member. To account for dif-
ferences in household structure, the household expendi-
ture was expressed as expenditure per adult equivalent
(AE) [18].
AE = (A+αK)θ
A = Number of adults in the household.
K = Number of children in the household.
α = Cost of a child relative to that of an adult. According
to Deaton and Zaidi (2002) this can be set to 0.3 for low-
income countries.
θ = Controls the extent of economies of the scale. This can
be set to 0.9 for low-income countries.
Ethical clearance
Ethical clearance was obtained at the National Institute
for Medical Research (NIMR), Dar es Salaam. Authorities
at district and ward levels also provided approval for the
study.
Results
Socio-demographic characteristics
A total of 269 adults, 135 mothers and 134 household
heads, consented to the quantitative study whereas four
were unwilling to be interviewed. Some 93 (69%) of the
heads were male and 41 (31%) were female. Among the
household heads, 90% were farmers and 77% had com-
pleted primary school and 19% secondary school. Among
the mothers, 97% were farmers, 80% had completed pri-
mary and 18% secondary school. The median number of
children in the interviewed households was 2, (range 1–
6). A majority of the households included 5–8 household
members.
Willingness to pay for ACT
Out of 265 respondents 244 (92%, 88%–95%) were will-
ing to pay TSh 500 for ACT for a sick child in the house-
hold and 147 (55%, 49%–61%) were willing to pay more
than TSh 500 (Figure 1). A total of 254 (96%, 93%–98%)
were willing to pay TSh 300. The median amount that
respondents were willing to pay was TSh 600.
WTP was not associated with education, occupation,
household size or number of children under five. The only
statistically significant association with WTP was being a
mother (unadjusted odds ratio = 2.0, CI = 1.2–3.4 and
adjusted odds ratio = 2.1, CI = 1.2–3.6). For the sake of
methodological clarity mothers that were also household
heads were excluded in this analysis. Little difference
between the adjusted odds ratio (adjusted for the effect of
the above mentioned variables) and the unadjusted odds
ratio indicates that mothers' higher WTP is less likely to be
due to confounding factors. Up to 72 (55%, 47%–64%)
of the mothers are involved in the malaria treatment-deci-
sion for a sick child but only 22 (17%, 11%–24%) could
also authorize the expenditure, either alone or together
with the husband. Some 79% of the mothers reported that
their husbands have to authorize the expenditure (Table
1).
Malaria was considered as the most serious disease in the
community by 97 mothers (76%, 68%–82%). A total of
100 mothers stated that an anti-malarial drug is the best
treatment for malaria, whereas 11 stated local herbs or
antipyretics. Some 24 respondents did not provide an
answer to this question or did not know. A total of 96
mothers (73%, 65%–80%) mentioned that mosquitoes
are the cause of malaria. Almost half of the mothers (43%,
34%–51%) reported that someone in the household had
suffered from malaria in the last two weeks. These meas-
ures were not, however, associated with WTP for ACT.
Household expenditures and assessment of previous fail-
ure to obtain malaria treatment were assessed from heads
and compared with WTP. The household expenditure
level, divided into quintiles, was not significantly related
to the WTP for ACT (Table 2). However wide confidence
intervals make the results uncertain. Up to 45 (34%,
27%–43%) of the respondents had failed access to
malaria treatment due to lack of money and they were
also less willing to pay for ACT (p = 0.033) (Table 2).
Ability to pay for ACT
A child in the rural area of the study was assumed to need
an ACT four times yearly and an adult once yearly [19,20].
The average price of an ACT was assumed to be US$ 1.0
per adult treatment dose and US$ 0.5 per child treatment
dose, based on information from Novartis and Sanofi-
Aventis [10,11]. Hence, the annual treatment cost would
average US$ 2.0 for a child and US$ 1.0 for an adult. These
costs were then multiplied by the number of adults and
children respectively in each study household. Accord-
ingly, a non-subsidized median household expenditure
for ACT was calculated at US$ 6.0. In the study area, the
cost of the introduced ACT in 2008 (Coartem®) was pro-
vided free of charge for children and at a cost of US$ 0.25
Malaria Journal 2008, 7:227 http://www.malariajournal.com/content/7/1/227
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for an adult dose. This would imply an annual median
household expenditure of US$ 0.75.
Comparisons were made of the opportunity costs of a)
unspecified non-subsidized ACT and b) subsidized Coar-
tem®. The annual median household expenditures for
health care, food, clothes & contributions, local transport
and all items taken together (US$ 182, range 28–1010)
were compared to these numbers. The opportunity cost
was expressed as percentage of the five expenditure cate-
gories (Figure 2). The opportunity costs of non-subsidized
ACT and subsidized Coartem® on the reported total
annual expenditure on food were 7.0% and 0.9% respec-
tively. The opportunity costs on the reported total annual
expenditure on health care were 33.0% and 4.2% respec-
tively.
According to official data [21], the average annual rural
household consumption expenditure in Tanzania was
US$ 636 [US$ 1 = TSh 876 [22]) in 2001. The median
annual household cost for ACT (US$ 6.0) represents 0.9%
of this. The median annual household cost of subsidized
Coartem® (US$ 0.75) represents 0.1% of this.
Perceptions and desired features of anti-malarial drugs
The general opinion about Fansidar, assessed through
focus group discussions and in-depth interviews with 24
respondents, was that the disadvantages outweigh the
Distribution of WTP for ACT among mothers and household heads, by price categoriesFigure 1
Distribution of WTP for ACT among mothers and household heads, by price categories. The statistical significant 
association with WTP was being a mother (unadjusted odds ratio = 2.0, CI = 2.1–3.4 and adjusted odds ratio = 2.1, CI = 1.2–
3.6). The dependent variable in the calculation was WTP ≤ TSh 500 respective WTP > TSh 500. The independent variables 
were household status, occupation, education, household size and number of children.
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Table 1: Decision-making on malaria treatment for a sick child under five as reported by mothers
Who decides to obtain an anti- malarial drug? (n = 130) Who authorizes the expenditure? (n = 130)
Mother 46 (35%, 28%–44%) 14 (11%, 7%–17%)
Husband 55 (42%, 34%–51%) 103 (79%, 71%–85%)
Together 26 (20%, 14%–28%) 8 (6%, 3%–12%)
Relatives/others 3 (2%, 1%–7%) 5 (4%, 2%–9%)
Total 130 (100%) 130 (100%)
The results are expressed with 95% confidence intervals.
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advantages. The main objections to Fansidar were poor
curative effect and an adverse effect, described as "hango-
ver". This implies extra expenses such as purchase of juice,
which can relieve this adverse effect. A "short regimen",
"few tablets" and "inexpensive" were positive comments
about Fansidar. A vast majority of the respondents do
think there is a need for a better anti-malarial drug than
Fansidar. The same respondents were then asked if they
had heard about combination therapy for malaria (dawa
ya mseto) or anti-malarial drugs containing artemisinin
(Artemedine®, Coartem®). Two of the 24 respondents had
heard about ACT/artemisinin drugs.
Table 2: WTP, expenditure and previous failure of accessing malaria treatment
Expenditure 
quintiles 
(TSh)
0–2760 2761–4300 4301–5680 5681–7680 7681–18200 Access failure No access 
failure
WTP ≤ TSh 
500
11 
(52%, 32%–
72%)
11 
(52%, 32%–
72%)
11 
(50%, 31%–
69%)
10 
(45%, 27%–
65%)
10 
(48%, 28%–
68%)
29 (64%, 50%–
77%)*
39 
(45%, 35%–
55%)
WTP > TSh 
500
10 
(48%, 28%–
68%)
10 
(48%, 28%–
68%)
11 
(50%, 31%–
69%)
12 
(55%, 35%–
73%)
11 
(52%, 32%–
72%)
16 
(36%, 23%–
50%)
48 
(55%, 45%–
65%)
Total 21 (100%) 21 (100%) 22 (100%) 22 (100%) 21 (100%) 45 (100%) 87 (100%)
WTP in relation to levels of expenditure (n = 107, p = 0.98) and previous failure of accessing malaria treatment (n = 132). Data was obtained from 
household heads. Results are expressed with 95% confidence intervals. (*) p = 0.033
Comparison of the opportunity costs of ACTFigure 2
Comparison of the opportunity costs of ACT. The calculated annual median household expenditure for non-subsidized 
ACT at US$ 6.0 is compared with the current (2008) local annual median household expenditure for subsidized Coartem® at 
US$ 0.75. The opportunity cost is expressed as percentage of five expenditure categories (n = 115).
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Mothers and heads (n = 245) were presented with a
number of features of a hypothetical anti-malarial drug
and were asked to quote features in order of importance
for frequent use (Figure 3). "Rapid effect" was quoted as
most important (33%, 28%–40%) followed by "no
adverse effects" (19%, 15%–25%) and "inexpensive"
(14%, 10%–19%). "Inexpensive" was quoted by 62%
(56%–68%) as at least one of three important features.
There was no statistically significant correlation between
the "most important" feature selected by the respondent
and the household status, occupation or education. Heads
of households with an average or below average expendi-
ture level, however, mentioned "inexpensive" as an
important feature more frequently than those with above
average expenditure level (68% compared to 44%, p =
0.021).
Discussion
Only half of the mothers and household heads were will-
ing to pay more than TSh 500 for a child's dose of ACT
and likely to be willing to pay US$ 6.0 per year, the
median estimated household cost for non-subsidized
ACT. However, 96% were willing to pay TSh 300.
In 2007 Tanzania changed its malaria treatment policy to
make Coartem® the first-line treatment for uncomplicated
malaria. For a three-year period it will be provided free to
all at governmental health care facilities through the Glo-
bal Fund support and be available for a cost of TSh 300–
500 (US$ 0.28–0.46) at specially designated shops
through the programme of Accredited Drug Dispensing
Outlets (ADDOs). In the study area Coartem® was thus
introduced in 2007, free for children below five years of
age but at a subsidized consumer cost of US$ 0.25 for an
adult dose.
The decisions to subsidize to the above levels in the public
health facilities and ADDOS appear to be well aimed,
since they cover almost all households' WTP for ACT.
However, the present policy may not continue after the
introductory phase. External funding is likely to be
needed in order for malaria interventions to be effectively
implemented and sustained. This finding supports earlier
studies including other malaria control measures
[12,13,23].
Mothers showed a higher WTP for ACT than male house-
hold heads. To what extent the mothers' higher WTP will
influence the decision behaviour is unclear. A vast major-
Most desired features of an anti-malarial drug according to mothers and headsFigure 3
Most desired features of an anti-malarial drug according to mothers and heads. The respondents were presented 
with a number of features of a hypothetical drug and were asked to quote features in orders of importance for frequent use in 
the household (n = 245).
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ity of authorizations of treatment-decisions for the chil-
dren are made by their husbands. This may however
conceal a complex process of decision-making within the
family before the household head's ultimate decision.
The median level of WTP of TSh 600 in the present study
without prior knowledge of ACT is in line with an earlier
study in Tanzania where mothers' WTP for ACT was TSh
650 to 750 after experiencing treatment of ACT to their
children [13].
Contingent valuation studies are criticized for being too
hypothetical and generating results with low validity,
since results depend on the choice of eliciting method.
The hypothetical scenario in this study was aimed at being
easily understood by the respondent and as realistic as
possible, although ACT was unknown to people prior to
the study. TIOLI was considered the most appropriate elic-
iting method since the malaria treatment usually is not
subject to bargaining but has the character of "buy it or
leave it". A main concern attributed to the CV method is
that the elicited monetary value correlates poorly with
reality, since respondents are subjected to a hypothetical
situation wherein their WTP is assessed. When hypotheti-
cal WTP has been compared to actual WTP, a divergence
between the hypothetical WTP and purchase behaviors
has been demonstrated [24-27]. Suggested factors behind
this divergence have been measurement biases overesti-
mating WTP, and legitimate changes in valuation with
time [16,28]. When the commodity is important to the
respondents, the discrepancy between hypothetical and
actual WTP may be smaller [29].
Measurement bias may have resulted from weak under-
standing of the questions. To improve the understanding,
the interviewers prepared explanations of questions in
Kihaya, although people in the area are often quite famil-
iar with both Kiswahili and Kihaya. This may have influ-
enced the wording of the questions but with a purpose of
increasing understanding for some respondents.
WTP is normally related to ATP [30]. However, WTP may
not directly reflect ATP in developing countries because
mobilization of resources in order to pay for health care
may require that basic needs such as food and education
are sacrificed with serious consequences for the house-
holds [31]. The expenditure level of households did not
correlate with WTP in this study. That could be due to pos-
sible measurement problems of this variable caused by
poor recall or that the economic differences between the
respondents were not prominent when using the included
expenditure categories. Including total food expenditure,
school-fees, household equipment and housing may have
been better for describing the economic differences
between the households. However, there was similarly no
correlation between WTP and the socio-economic status
in the previous study from Tanzania [13].
There is a large discrepancy between the total annual
median expenditure estimated in the present study (US$
182) and the official data (US$ 636). Excluded expendi-
ture items in this study like school-fees, housing and
household equipment as well as the benefit of food pro-
duced by the household in this fertile area, may explain
some of the discrepancy.
WTP was significantly correlated with previous failure of
accessing malaria treatment. "Previous failure of accessing
malaria treatment" may represent a better variable than
"expenditures" for estimating the ATP. It might be easier
to remember and report than expenditures. It may also be
more socially desirable to describe oneself as having poor
financial access to drugs than having low economic status.
It has been pointed out that the tendency to provide
answers perceived to be the desired response, social desir-
ability bias, should be considered in WTP studies [32].
Other studies have found that the contingent valuation
method may be influenced by the fact that respondents
deliberately understate their WTP to influence the price of
a new product, so called strategic bias [33]. However, in
the present study, respondents had little prior knowledge
of ACT and probably did not see any gain in projecting
low WTP for it.
Among desired features of an anti-malarial drug, the
respondents considered "rapid effect" and "no adverse
effects" more important than "inexpensive" or "good cur-
ative effect". This suggests that recurrence of malaria may
not be perceived as an indicator of ineffective treatment
and that the immediate relief of symptoms is most impor-
tant.
The median household cost of an ACT as 0.9% of the total
annual average household expenditures in Tanzania
would in a rich country like Sweden represent US$ 332, as
estimated from official data from 2001 [21,22,34]. Subsi-
dized Coartem's® annual median household cost as 0.12%
of the total annual average household expenditures would
represent US$ 42.
Conclusion
Small fluctuations in price may have substantial impact
on WTP and treatment seeking behaviour. Male heads of
households are less willing to pay than the caregivers of
children. This is to be considered when designing suitable
financial strategies for making first-line anti-malarial
drugs available to families and when sensitising people
with information on recommended malaria treatment.
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The upper limit of the price for a child's dose of ACT
should not exceed Tsh 500 (US$ 0.46), so as to be finan-
cially accessible and used in this community. Subsidies
are, therefore, needed to make ACT affordable to the aver-
age households in this and other low-income settings.
This study also shows that before the introduction of ACT
as first-line treatment, there was a wish and need for a
new, better, affordable and reliable anti-malarial drug.
The present study, however, generally supports the deci-
sion to subsidize Coartem® to a consumer price of TSh 0–
500 as it appears to cover almost all households' WTP for
ACT. Since malaria control has been proven to have high
cost-effectiveness [35], both national and external fund-
ing should, therefore, ensure that the present policy of
ACT subsidy is sustained.
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